AR042511A1 - Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico - Google Patents

Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico

Info

Publication number
AR042511A1
AR042511A1 ARP030104684A ARP030104684A AR042511A1 AR 042511 A1 AR042511 A1 AR 042511A1 AR P030104684 A ARP030104684 A AR P030104684A AR P030104684 A ARP030104684 A AR P030104684A AR 042511 A1 AR042511 A1 AR 042511A1
Authority
AR
Argentina
Prior art keywords
hygroscopic
drug
polymer
composition
composition according
Prior art date
Application number
ARP030104684A
Other languages
English (en)
Spanish (es)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR042511A1 publication Critical patent/AR042511A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
ARP030104684A 2002-12-19 2003-12-17 Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico AR042511A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43514702P 2002-12-19 2002-12-19
US43502202P 2002-12-19 2002-12-19
US43542202P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
AR042511A1 true AR042511A1 (es) 2005-06-22

Family

ID=32719157

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030104684A AR042511A1 (es) 2002-12-19 2003-12-17 Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico
ARP030104716A AR042536A1 (es) 2002-12-19 2003-12-18 Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030104716A AR042536A1 (es) 2002-12-19 2003-12-18 Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente

Country Status (17)

Country Link
US (2) US20040197411A1 (https=)
EP (2) EP1575563B1 (https=)
JP (2) JP2006513238A (https=)
AR (2) AR042511A1 (https=)
AT (1) ATE353633T1 (https=)
AU (2) AU2003298010A1 (https=)
BR (2) BR0317392A (https=)
CA (2) CA2511385A1 (https=)
DE (1) DE60311875T2 (https=)
ES (1) ES2280835T3 (https=)
HN (1) HN2003000417A (https=)
MX (2) MXPA05006802A (https=)
NL (1) NL1025069C2 (https=)
PE (1) PE20040972A1 (https=)
TW (2) TW200423971A (https=)
UY (1) UY28138A1 (https=)
WO (2) WO2004060352A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004060352A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
WO2006004480A1 (en) * 2004-07-02 2006-01-12 Radi Medical Systems Ab Smokeless toabacco product
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
NZ572702A (en) * 2006-06-06 2011-09-30 Tibotec Pharm Ltd Process for preparing spray dried formulations of etravirine in microcrystalline cellulose
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ZA200905094B (en) * 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof
EP2185472A1 (en) * 2007-08-30 2010-05-19 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
KR101499533B1 (ko) * 2008-02-15 2015-03-09 주식회사 씨티씨바이오 콜린 알포세레이트 함유 약학 제제
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101172699B1 (ko) 2011-05-16 2012-08-09 한국프라임제약주식회사 콜린알포세레이트를 함유하는 약학 제제, 및 그의 제조방법
US20140130759A1 (en) 2011-07-07 2014-05-15 The Lubrizol Corporation Lubricant Providing Improved Cleanliness For Two-Stroke Cycle Engines
CN102525992A (zh) * 2012-03-09 2012-07-04 徐奎 L-α-甘油磷酸胆碱薄膜衣片及其制备方法
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2013175505A1 (en) * 2012-05-21 2013-11-28 Hetero Research Foundation Elvitegravir solid dispersion
WO2017161387A1 (en) * 2016-03-18 2017-09-21 Reid Christopher Brian Compositions of natural extracts and use thereof in methods for preventing or treating diseases
EP3021832B9 (en) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2930033C (en) * 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
GB2525170A (en) * 2014-04-07 2015-10-21 Nokia Technologies Oy Stereo viewing
CN104739776A (zh) * 2015-04-15 2015-07-01 福州乾正药业有限公司 左卡尼汀的固体分散体组合物及其制备方法和药物应用
WO2017013591A1 (en) * 2015-07-22 2017-01-26 Leiutis Pharmaceuticals Pvt Ltd Stabilized liquid formulation of levothyroxine
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN111902422A (zh) * 2018-03-30 2020-11-06 株式会社钟化 含有氧化型谷胱甘肽的固体组合物及其制造方法
CN112316678A (zh) * 2020-10-12 2021-02-05 常州市永勃机械有限公司 一种变电站柜体用驱潮剂制备工艺制备方法
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835187A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
JPH02218621A (ja) * 1989-02-20 1990-08-31 Nippon Chemiphar Co Ltd 徐放性製剤
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
WO1995013794A1 (en) * 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
JPH10182448A (ja) * 1996-12-24 1998-07-07 Zensei Yakuhin Kogyo Kk 圧縮製剤用組成物の製造方法
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DK1265859T3 (da) * 2000-03-24 2006-05-01 Pharmacia Corp Amidinoforbindelser der er nyttige som nitrogenoxidsyntaseinhibitorer
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
WO2004060352A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug

Also Published As

Publication number Publication date
AU2003298010A1 (en) 2004-07-29
TW200413006A (en) 2004-08-01
WO2004060353A9 (en) 2004-10-07
ES2280835T3 (es) 2007-09-16
WO2004060352A8 (en) 2005-09-15
WO2004060352A1 (en) 2004-07-22
EP1575563B1 (en) 2007-02-14
PE20040972A1 (es) 2004-12-14
EP1575564A1 (en) 2005-09-21
TW200423971A (en) 2004-11-16
EP1575563A1 (en) 2005-09-21
CA2511385A1 (en) 2004-07-22
WO2004060353A1 (en) 2004-07-22
US20040197411A1 (en) 2004-10-07
JP2006514052A (ja) 2006-04-27
DE60311875T2 (de) 2007-08-30
CA2509261A1 (en) 2004-07-22
NL1025069C2 (nl) 2005-02-16
UY28138A1 (es) 2004-08-31
AU2003296948A1 (en) 2004-07-29
ATE353633T1 (de) 2007-03-15
HN2003000417A (es) 2005-11-01
BR0317103A (pt) 2005-10-25
US20050013856A1 (en) 2005-01-20
NL1025069A1 (nl) 2004-07-01
JP2006513238A (ja) 2006-04-20
MXPA05006802A (es) 2005-09-08
DE60311875D1 (de) 2007-03-29
MXPA05005667A (es) 2005-07-26
AR042536A1 (es) 2005-06-22
BR0317392A (pt) 2005-12-20

Similar Documents

Publication Publication Date Title
AR042511A1 (es) Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
UY27991A1 (es) Derivados de pirrolidona domo inhibidores de maob
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
BRPI0506622A (pt) éster biciclo derivado; um intermediário na produção do éster biciclo derivado; produto farmacêutico contendo um ingrediente ativo do éster biciclo derivado; inibidor dpp-iv contendo um ingrediente ativo do éster biciclo derivado; agente terapêutico para uma doença envolvendo dpp-iv contendo um ingrediente ativo do éster biciclo derivado, e agente terapêutico
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
DE69813571D1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
JP2004532828A5 (https=)
DE60036924D1 (de) 5-ht1f agonisten
DK412788D0 (da) Farmaceutisk middel til brug ved behandling af uraemi
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
HUP0102075A2 (hu) Stabil mitoxantron-oldatok, eljárás az előállításukra
PE20040903A1 (es) Derivados de nucleosido antivirales
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
MA27662A1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
BR0207058A (pt) Método para reduzir doença associada com transfusão e efeitos adversos no plasma para aumentar a pureza e segurança de múltiplos componentes derivados de sangue, crioprecipitado enriquecido, plasma crio-exaurido, e, cola de fibrina
ES2196779T3 (es) Composiciones farmaceuticas.
NO20006611D0 (no) Karboksylsyre og hydroksamsyre metalloprotease- inhibitorforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FB Suspension of granting procedure